RESUMEN
OBJECTIVES: Antifungal triazole derivatives have been studied as possible alternatives for the treatment of Chagas' disease. Voriconazole has demonstrated in vitro activity against Trypanosoma cruzi, but its efficacy in vivo has not yet been tested. We aimed to determine the effect of voriconazole in a murine model of acute T. cruzi infection. METHODS: Treatment efficacy was evaluated by comparing parasitaemia, mortality and organ involvement (by histological examination) of infected mice. RESULTS: Treatment with voriconazole significantly lowered parasitaemia and mortality compared with controls, reduced the percentage of mice with amastigote nests in heart and skeletal muscle and moderately decreased myocardial inflammation. CONCLUSIONS: Our findings support the potential of voriconazole for the treatment of acute Chagas' disease and motivate future animal studies using varying doses and treatment schemes. Further evaluation of voriconazole for clinical use in human Chagas' patients is warranted.
Asunto(s)
Antiprotozoarios/uso terapéutico , Enfermedad de Chagas/tratamiento farmacológico , Pirimidinas/uso terapéutico , Triazoles/uso terapéutico , Trypanosoma cruzi/efectos de los fármacos , Estructuras Animales/parasitología , Animales , Enfermedad de Chagas/mortalidad , Enfermedad de Chagas/parasitología , Enfermedad de Chagas/patología , Modelos Animales de Enfermedad , Femenino , Histocitoquímica , Ratones , Ratones Endogámicos BALB C , Parasitemia/tratamiento farmacológico , Análisis de Supervivencia , VoriconazolRESUMEN
With the aim of investigating if delivery of benznidazole (BNZ) to liver could be increased by incorporating the drug in multilamellar liposomes, single bolus of free BNZ or liposomal BNZ formulations (MLV-BNZ) composed of HSPC:DSPG:Chol 2:1:2 (mol/mol/mol) at 0.7% (w/w) drug/total lipid ratio, were injected by intramuscular (i.m.), subcutaneous (s.c.) and intravenous (i.v.) routes, at 0.2 mg BNZ/kg, in rats. The resulting blood concentrations were followed along 9 h post-injection (p.i.) and drug accumulation in liver was determined after 4 and 9 h p.i. Only upon i.v. injection of MLV-BNZ, a threefold higher BNZ accumulation in liver was obtained, together with blood BNZ concentrations of 1.1 microg/ml (30% lower than the blood BNZ concentration achieved upon i.v. administration of free drug) occurred 4 h p.i. However, such increased liver uptake of BNZ, raised twice a week had no effect on parasitaemia levels of mice infected with the RA strain of Trypanosoma cruzi. Our results indicate that the relationship between increased selectivity for an infected tissue and therapeutic effect is not always straightforward, at least for the MLV-BNZ regimen used in the present study.
Asunto(s)
Hígado/metabolismo , Nitroimidazoles/administración & dosificación , Nitroimidazoles/farmacocinética , Tripanocidas/administración & dosificación , Tripanocidas/farmacocinética , Animales , Enfermedad de Chagas/tratamiento farmacológico , Femenino , Inyecciones Intravenosas , Liposomas , Hígado/parasitología , Ratones , Ratones Endogámicos BALB C , Nitroimidazoles/química , Parasitemia/tratamiento farmacológico , Tamaño de la Partícula , Fosfolípidos/química , Ratas , Ratas Wistar , Distribución Tisular , Tripanocidas/química , Trypanosoma cruzi/efectos de los fármacosRESUMEN
Th1-type immune response plays a critical role in resistance to Trypanosoma cruzi infection. We asked whether a synthetic oligodeoxynucleotide that contains immunostimulatory CpG motifs (CpG ODN), known to promote a Th1 response, could act as an adjuvant in immunization with parasite antigens. Mice immunized with a whole homogenate (WH) of T. cruzi antigens co-administered with CpG ODN presented high titers of T. cruzi antibodies (IgG2a isotype), strong delayed type hypersensitivity and a Th1-dominated (IFN-gamma and IL-12) cytokine profile. Furthermore, WH plus CpG ODN protected mice from challenge with an otherwise lethal dose of bloodstream trypomastigotes. As reported for leishmaniasis and malaria, CpG ODN holds considerable promise as an adjuvant for future vaccines against T. cruzi.
Asunto(s)
Adyuvantes Inmunológicos/farmacología , Anticuerpos Antiprotozoarios/biosíntesis , Fosfatos de Dinucleósidos/farmacología , Oligodesoxirribonucleótidos/farmacología , Vacunas Antiprotozoos/inmunología , Células TH1/fisiología , Trypanosoma cruzi/inmunología , Animales , Antígenos de Protozoos/inmunología , Enfermedad de Chagas/prevención & control , Citocinas/biosíntesis , Femenino , Hipersensibilidad Tardía/etiología , Inmunización , Ratones , Ratones Endogámicos BALB CRESUMEN
An 80-kDa Trypanosoma cruzi urinary antigen (UAg) was affinity-purified from the urine of infected dogs. We demonstrated that UAg is structurally and functionally related to proteins belonging to the transferrin family, as shown by amino acid sequence and iron binding experiments. Nevertheless, monoclonal antibodies raised against UAg specifically and selectively recognized this parasite's circulating antigen. The existence of an 80-kDa T. cruzi antigen co-migrating with UAg could be confirmed when epimastigotes were metabolically labelled with [35S] methionine and then immunoprecipitated with the above mentioned antibodies. We conclude that UAg is an iron-binding T. cruzi component eliminated in the urine of the infected host.
Asunto(s)
Antígenos de Protozoos/metabolismo , Enfermedad de Chagas/inmunología , Hierro/metabolismo , Trypanosoma cruzi/inmunología , Secuencia de Aminoácidos , Animales , Anticuerpos Monoclonales/inmunología , Antígenos de Protozoos/inmunología , Antígenos de Protozoos/aislamiento & purificación , Enfermedad de Chagas/orina , Perros , Electroforesis en Gel de Poliacrilamida , Epítopos , Datos de Secuencia MolecularRESUMEN
We analyzed the biological role of nitric oxide (NO) during murine Trypanosoma cruzi infection. Infection of mice with T. cruzi markedly increased NO synthesis. Administration of N-nitro-L-arginine methyl-esther (L-NAME) intraperitoneally or intragastrically diminished endogenous NO synthesis and resistance of mice to acute infection with three biologically different strains of T. cruzi. Mice protected against challenge with T. cruzi by transfer of T-cell-enriched populations from chronically infected animals, showed higher serum nitrate levels than controls non-transferred, or transferred, with T cells from non-immune mice. Administration of L-NAME abrogated transfer of resistance, suggesting NO participation in this process. Depletion of T cells from the transferred population abolished both protection and NO3- increase. On the contrary, mice chronically infected with T. cruzi showed no increased parasitemia or death upon treatment with L-NAME. The NO donor drug S-nitroso-acetyl-penicillamine was able to kill tissue culture or bloodstream trypomastigotes in vitro at biologically relevant concentrations. Conversely, NO appeared not to play a role in formation of inflammatory foci during T. cruzi infection, since infected mice treated with L-NAME showed no reduced inflammation.
Asunto(s)
Enfermedad de Chagas/inmunología , Enfermedad de Chagas/patología , Óxido Nítrico/fisiología , Enfermedad Aguda , Animales , Enfermedad de Chagas/prevención & control , Enfermedad Crónica , Inmunidad Innata , Ratones , Ratones Endogámicos BALB C , Óxido Nítrico/inmunología , Óxido Nítrico/metabolismo , Linfocitos T/inmunología , Linfocitos T/patología , Trypanosoma cruzi/inmunologíaRESUMEN
Mice lacking CD4 and/or CD8 gene expression, generated by embryonic stem-cell technology, were used to study the role of CD4+ and CD8+ cells in the resistance to the acute infection with virulent (Tulahuén and RA) or mild (CA-I) strains of Trypanosoma cruzi. The presence of both CD4+ and CD8+ cells contributed to the survival of mice infected with T. cruzi, and each T-cell subtype was able to sustain protective functions in the absence of the other one. However, in certain host-parasite combinations, CD8+ cell-independent mechanisms were able to control the parasite load. Moreover, CD8- mice chronically infected with a low virulent strain of T. cruzi were protected from an otherwise lethal challenge with the parasite. A different organ distribution of parasite nests was observed when mutant (but not wild type) animals infected with different parasite strains were compared. CD4- mice produced high levels of IgG antibodies against peptide antigens or a whole homogenate from the parasite after infection with CA-I strain. A dramatic enhancement of IgG1- and IgG2a-specific antibodies was observed.
Asunto(s)
Antígenos de Protozoos/inmunología , Antígenos CD4/fisiología , Linfocitos T CD4-Positivos/inmunología , Antígenos CD8/fisiología , Linfocitos T CD8-positivos/inmunología , Enfermedad de Chagas/inmunología , Síndromes de Inmunodeficiencia/inmunología , Trypanosoma cruzi/inmunología , Secuencia de Aminoácidos , Animales , Antígenos CD4/genética , Antígenos CD8/genética , Enfermedad de Chagas/complicaciones , Antígenos H-2/inmunología , Inmunoglobulina G/inmunología , Síndromes de Inmunodeficiencia/complicaciones , Ratones , Ratones Noqueados , Datos de Secuencia Molecular , Trypanosoma cruzi/patogenicidad , VirulenciaRESUMEN
We analysed the production of nitric oxide (NO) intermediates by cells from BALB/c mice infected with either virulent (Tulahuén or RA) or avirulent (CA-1) strains of Trypanosoma cruzi. Peritoneal or spleen cells from mice infected with T. cruzi released NO when incubated without further stimuli. Cells from mice during the acute stage of infection accumulated higher levels of inducible NO synthase mRNA and produced both, before and after lypopolysaccharide stimulation, higher amounts of NO than cells from mice chronically infected with T. cruzi. NO synthesis showed similar kinetics in connection with all three strains of T. cruzi, but cells from mice inbred with the Tulahuén or RA strains released higher levels of IFN-gamma, an activator of the NO pathways, than cells from mice infected with the CA-1 strain. In vivo administration of L-Ng-monomethyl-L-arginine (L-NMMA), a competitive inhibitor of NO synthase, increased the susceptibility of mice to T. cruzi. We conclude that infection with T. cruzi induces NO production, and suggest that NO plays a role in the resistance against the parasite.
Asunto(s)
Enfermedad de Chagas/metabolismo , Óxido Nítrico/biosíntesis , Aminoácido Oxidorreductasas/metabolismo , Animales , Arginina/análogos & derivados , Arginina/farmacología , Secuencia de Bases , Cartilla de ADN , Modelos Animales de Enfermedad , Femenino , Interferón gamma/metabolismo , Ratones , Ratones Endogámicos BALB C , Datos de Secuencia Molecular , Óxido Nítrico/antagonistas & inhibidores , Óxido Nítrico Sintasa , Cavidad Peritoneal/citología , ARN Mensajero/metabolismo , Bazo/citología , Trypanosoma cruzi/patogenicidad , Virulencia/efectos de los fármacos , omega-N-MetilargininaRESUMEN
We studied the effect of in vivo administration of anti-gamma-IFN and anti-IL-4 monoclonal antibodies on the resistance of mice against myotropic and reticulotropic strains of Trypanosoma cruzi. Anti-gamma-IFN treatment augmented the susceptibility of mice when infected with the reticulotropic RA and Tulahuén strains of T. cruzi but did not alter the course of infection with the myotropic CA-I strain of the parasite. In vivo administration of anti-IL-4 enhanced the resistance of mice when infected with either Tulahuén or RA strains but did not affect the course of parasitemia when infected with CA-I. The possible biological relevance of these observations is discussed.
Asunto(s)
Enfermedad de Chagas/inmunología , Interferón gamma/antagonistas & inhibidores , Interleucina-4/antagonistas & inhibidores , Trypanosoma cruzi/inmunología , Animales , Anticuerpos Monoclonales/administración & dosificación , Enfermedad de Chagas/parasitología , Enfermedad de Chagas/prevención & control , Femenino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Especificidad de la Especie , Trypanosoma cruzi/patogenicidadRESUMEN
The ELISA technique for detection of T. cruzi circulating antigens (cAg) and immune complexes (CIC) in the sera of chronic chagasic patients was field-tested in a well-known endemic area of Argentina (San Luis province). Of 215 individuals screened, 51 were positive for ELISA-CIC and 45 for ELISA-cAg. Seventy four subjects were considered por T. cruzi-infected, as they showed serologic reactivity at least by two different techniques. In this group, 49 (66.21%) were ELISA-CIC positive, whereas in 43 (58.11%) of them cAg was found by ELISA. Unspecific reactions were observed in only 2 cases with reactive serology for Chagas disease. Within the group considered as noninfected, a false-positive outcome was obtained at low dilution by one of the serologic tests in 16 (11.35%) of 141 individuals. These sera yielded consistently negative results by ELISA-CIC and cAg, showing the utility of antigen detection in situations of conflictive serology. While antibody determination merely provides an indirect proof of infection, our ELISA tests for demonstration of T. cruzi-specific antigenic fractions in the host's circulation allow a parasitologic diagnosis in chronic patients, with higher sensitivity than that exhibited by traditional methods for detection of the whole parasite.